Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib

NCT02604342 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

119

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Alectinib
DRUG: Docetaxel
DRUG: Pemetrexed

Sponsor

Hoffmann-La Roche